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Abstract
Background: Numerous pre-clinical studies and clinical trials demonstrated that induction of antibodies to the b-
amyloid peptide of 42 residues (Ab42) elicits therapeutic effects in Alzheimer’s disease (AD). However, an active
vaccination strategy based on full length Ab42 is currently hampered by elicitation of T cell pathological
autoreactivity. We attempt to improve vaccine efficacy by creating a novel chimeric flu vaccine expressing the
small immunodominant B cell epitope of Ab42. We hypothesized that in elderly people with pre-existing memory
Th cells specific to influenza this dual vaccine will simultaneously boost anti-influenza immunity and induce
production of therapeutically active anti-Ab antibodies.
Methods: Plasmid-based reverse genetics system was used for the rescue of recombinant influenza virus
containing immunodominant B cell epitopes of Ab42 (Ab1-7/10).
Results: Two chimeric flu viruses expressing either 7 or 10 aa of Ab42 (flu-Ab1-7 or flu-Ab1-10) were generated and
tested in mice as conventional inactivated vaccines. We demonstrated that this dual vaccine induced
therapeutically potent anti-Ab antibodies and anti-influenza antibodies in mice.
Conclusion: We suggest that this strategy might be beneficial for treatment of AD patients as well as for
prevention of development of AD pathology in pre-symptomatic individuals while concurrently boosting immunity
against influenza.
Introduction
Alzheimer’s disease (AD) is the most common form of
dementia in the elderly which is clinically characterized
by progressive loss of memory and general cognitive
decline. The neuropathological features of AD include
neurofibrillary tangles (NFT), deposition of soluble
(monomeric, oligomeric) and insoluble fibrillar Ab
(senile plaques) forms, and neuronal loss in affected
brain regions [1]. Pre-clinical and clinical trials have
revealed that anti-Ab antibodies are beneficial in clear-
ing Ab deposits [2-13]. The first clinical trial of active
immunization against Ab was of the vaccine AN 1792,
which comprised of fibrillar Ab42 formulated in a strong
Th1-type biasing adjuvant, QS21. Patients treated with
this vaccine were suffering mild-to-moderate AD. The
trial was halted due to development of meningoence-
phalitis in some of the patients, which was believed to
be associated with anti-Ab specific T cell immune
responses [8,9,14-16]. One possible way to avoid these
side effects is the replacement of the self-T helper epi-
tope(s) present in the Ab42 peptide by a foreign epitope
(s) while leaving self-B cell epitope(s) of Ab42 intact.
Another important, but overlooked, result from the AN-
1792 clinical trial was that the majority of AD patients
generated only low titers of anti-Ab antibodies, and
approximately 50% of the patients failed to produce a
measurable antibody response [12,17]. The cause of the
low anti-Ab antibody titers and non-responsiveness
observed in AN-1792 trial could be due to immune tol-
erance induced by self-Ab42 antigen. The mammalian
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specific to self-molecules; however, B cell tolerance is
not rigorous, while T cell tolerance is more stringent
[18,19]. Previously we suggested that replacement of the
Th cell epitope of Ab42 by a foreign Th epitope will
help to overcome not only T cell tolerance induced by
self antigen, but also side effects caused by autoreactive
T cells. In our previous work we generated peptide- and
DNA-based epitope vaccines based on amyloid-specific
B-cell epitopes Ab1-15 or Ab1-11 attached to the promis-
cuous foreign Th epitope pan HLA DR-binding peptide
(PADRE) and demonstrated the feasibility of this strat-
egy in wild-type [20-22] and APP/Tg mice [23-25]. In
this study we hypothesized that for therapeutic purposes
AD epitope vaccines could be delivered to patients by a
conventional viral vaccine [26]. Specifically, chimeric
influenza viruses expressing the B cell epitope of Ab
may not only induce anti-viral immunity, but also gen-
erate higher titers of anti-Ab antibodies in adult indivi-
duals with pre-existing influenza virus-specific memory
Th cells. Accordingly, we generated and tested for the
f i r s tt i m et h ei m m u n o g e n i c i t ya n dp r o t e c t i v ee f f i c a c yo f
chimeric inactivated flu virus vaccines expressing 1-7 or
1-10 aa of Ab42 (flu-Ab1-7 and flu-Ab1-10)i nm i c ea n d
demonstrated that these dual vaccines induced thera-
peutically potent anti-Ab and anti-influenza antibodies.
Materials and methods
Mice
Female, 5-6 week-old C57Bl/6 mice were obtained from
the Jackson Laboratory (MN). All animals were housed
in a temperature- and light cycle-controlled animal facil-
ity at the Institute for Memory Impairments and Neuro-
logical Disorders (MIND), University of California Irvine
(UCI). Animal use protocols were approved by the Insti-
tutional Animal Care and Use Committee of UCI and
were in accordance with the guidelines of the National
Institutes of Health.
Generation and purification of chimeric virus
Figure 1A illustrates the plasmid-based reverse genetic
rescue system [26,27] used to generate chimeric influ-
enza A/WSN/33 (H1N1) viruses expressing B cell epi-
topes Ab1-10 (WSN-Ab1-10), or Ab1-7 (WSN-Ab1-7)f r o m
Ab42. This system includes four protein expression plas-
mids encoding the three influenza virus polymerase pro-
teins (PB1, PB2 and PA) and nucleoprotein (NP), plus
eight transcription plasmids encoding the eight viral
gene segments. Sequences encoding B cell epitope of
amyloid-b were cloned into the HA segment near the
receptor binding site. Chimeric and wild-type viruses
were rescued in Madin-Darby canine kidney (MDCK)/
293T cell co-cultures, and the identity of the rescued
viruses was confirmed by RT-PCR and restriction/
sequence analysis of the HA gene segment containing
the engineered foreign sequence as previously described
[27]. Chimeric viruses were further grown in embryo-
nated 10 day-old hen eggs. Viruses were purified from
allantoic fluid by centrifugation through a 30% sucrose
cushion. Protein concentration in purified virus samples
was determined by the Bio-Rad protein assay (Bio-RAD,
CA) and the purity of the samples was analyzed by
SDS-PAGE (Bio-RAD, CA). The protein bands were
visualized by coomassie blue staining.
Western Blotting and Dot Blot Assay
Presence of Ab epitope in WSN-Ab1-10 or WSN-Ab1-7
was confirmed by Western blot using anti-Ab 20.1
monoclonal antibody (gift from Dr. Van-Nostrand,
Stony Brook University). Influenza proteins NP, HA and
M1 were visualized by staining with rabbit polyclonal
anti-WSN serum (gift of Drs. Thomas Moran and Peter
Palese, Mount Sinai School of Medicine). Western Blot
was done as described in [28].
Binding of anti-Ab1-10 sera to different forms of Ab42
peptide was analyzed by Dot Blot assay. Briefly, we
applied 1 μl of monomeric, oligomeric, or fibrillar forms
of Ab42 and irrelevant peptide (100 μM each) to a nitro-
cellulose membrane as described [24]. After blocking
and washing, the membranes were probed with sera of
mice immunized with either WSN-Ab1-10 or WSN-WT
formalin-inactivated virus vaccines, or with antibodies
6E10 specific for Ab N-terminal region spanning aa 3-8
(1:3000; Covance Inc., NJ) and anti-oligomer A11
(1:500; Sigma-Aldrich, MO). Sera were used at dilution
1:200. The membranes were incubated with appropriate
horseradish peroxidase-conjugated anti-mouse or anti-
rabbit (only for A11) antibodies (1:1000; Santa Cruz Bio-
technology, Inc., CA). Blots were developed using Lumi-
nol reagent (Santa Cruz Biotechnology, Inc., CA) and
exposed to HyBlot CL Autoradiography Film (Denville
Scientific Inc., NJ).
Immunofluorescence
Expression of Ab epitopes by chimeric viruses was ana-
lyzed by immunofluorescence of infected cells. Briefly,
confluent MDCK monolayers were infected with wild-
type (WSN-WT) influenza virus or chimeric viruses
WSN-Ab1-10 or -Ab1-7 . Twelve hours post-infection
cells were washed with PBS, fixed with 1% paraformal-
dehyde, permeabilized with 0.1% Triton X-100, blocked
with 1% BSA, and then incubated with anti-Ab (20.1) or
anti-HA (2G9) MoAb. Infected cells were then incu-
bated with a secondary anti-mouse FITC-conjugated
antibody and visualized under a fluorescence microscope
at ×20 magnification.
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Hemagglutination inhibition (HI) assays were performed
using standard methods [29]. Receptor-destroying
enzyme (Vibrio cholera filtrate; Sigma-Aldrich, MO)-
treated serum as well as the anti-Ab 20.1, anti-HA
(2G9; gift of Drs. Thomas Moran and Peter Palese,
Mount Sinai School of Medicine) and irrelevant anti-
IRF3 antibodies (Invitrogen, CA) were used in these
assays. Briefly, two fold dilutions of the indicated mono-
clonal antibodies or RDE-treated serum from immu-
nized and control mice were prepared in saline solution.
The diluted monoclonal antibodies or serum were then
incubated with 8 hemagglutination assay (HA) units of
wild-type WSN or chimeric virus. After 1 h incubation
at room temperature, chicken red blood cells (RBC)
were added to each well (final concentration of 0.5%)
and incubated for 40 minutes on ice. The HI titer is
expressed as the reciprocal of the highest dilution of
serum able to inhibit hemagglutination.
Preparation of viral stocks and immunization of mice
Viruses were grown in MDCK cells using DMEM con-
taining 0.3% BSA, 1 μg Trypsin-TPCK/mL, penicillin,
and streptomycin. After 48 h post-infection, the super-
natants were collected and the viruses were pelleted by
centrifugation at 25K rpm for 2 h on a 30% sucrose
cushion (NTE buffer; 100 mM NaCl; 10 mM Tris-HCl,
pH 7.4; 1 mM EDTA). The pellets were resuspended in
NTE buffer and re-pelleted by centrifugation at 25K for
90 min in NTE buffer. The pellets were resuspended to
1 mg/ml concentration and inactivated using formalde-
hyde for 2 days at 4°C. To confirm complete inactiva-
tion of virus, formaldehyde treated viruses were injected
into 10 d old embryonated eggs and viral replication
was examined by hemagglutination assay. Mice were
immunized with indicated amount of inactivated viruses
formulated in Quil A adjuvant administrated subcuta-
neously (s.c.) at biweekly intervals. Sera were collected
12 days after each immunization.
Detection of anti-Ab and anti-HA antibody responses
using ELISA
Concentration of anti-Ab antibody in sera of immunized
and control mice was measured as described previously
[21]. Briefly, wells of 96-well plates (Immulon II; Dynax
Laboratories, VA) were coated with 2.5 μM soluble Ab42
(pH 9.7, o/n, and 4°C) or 10 μg/ml protein from inacti-
vated WSN-WT virus. Wells were then washed and
blocked, and sera from experimental mice were added
to the wells at different dilutions. After incubation and
washing, HRP-conjugated anti-mouse IgG (Jackson
ImmunoResearch Laboratories, ME) was used as
Figure 1 Preparation of chimeric virus: (A) Schematic presentation of the rescue strategy of WSN-Ab1-10 chimeric virus. (B) SDS-PAGE
and coomassie staining of purified chimeric (WSN-Ab1-10) and wild-type (WT) viruses. (C) WB analysis of purified virus using anti-Ab antibody
revealed the chimeric HA-Ab1-10 protein of the correct size. (D) Proteins corresponding to NP, HA and M1 were detected in WB analysis of
purified virus using anti-WSN polyclonal serum.
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and the reaction was developed by adding 3,3’,5,5’tetra-
methylbenzidine (TMB) (Pierce, IL) substrate solution
and stopped with 2M H2SO4. The optical density (OD)
was read at 450 nm (Biotek, Synergy HT, VT), and anti-
Ab antibody concentrations were calculated using a cali-
bration curve generated with 6E10 monoclonal antibody
(Signet, MA). In order to determine half-max binding
values of anti-viral antibodies we plotted the OD450
values against the serum dilution as described [30,31].
From this plot we determined half-maximal antibody
titers (HMAT) by dividing the highest OD450 value in
the dilution range of each serum sample by two. Initial
dilution of sera in these experiments was 1:500 and they
were serially diluted up to 1:500000. All anti-Ab concen-
trations and HMAT were determined in individual mice.
Detection of Ab plaques in human brain tissues
Sera from immunized mice were screened for the ability
to bind to human Ab plaques using 50 μmb r a i ns e c -
tions of formalin-fixed cortical tissue from a severe AD
case (received from Brain Bank and Tissue Repository,
MIND, UC Irvine) using immunohistochemistry as
described previously [20]. A digital camera (Olympus,
Tokyo, Japan) was used to capture images of the plaques
at an × 4 magnification. The binding of anti-Ab sera to
the b-amyloid plaques was blocked by 2.5 mM of Ab42
peptide as described [20].
Neurotoxicity Assay
Cell culture MTT assay was performed as described pre-
viously with minor modifications [24,32]. Human neuro-
blastoma SH-SY5Y cells (ATCC, VA) were used and
aliquoted into 96-well plates (Immulon II; Dynax
Laboratories, VA) at approximately 2 × 10
4 cells per
well in 100 ml of medium (45% DMEM, 45% Ham’s
modification of F-12, 10% FBS and 2 mM L-glutamine)
and incubated for 24 h in 5% CO2 atmosphere at 37°C
to allow attachment to the bottom of the wells. Ab oli-
gomers and fibrils were prepared as we described pre-
viously [24]. Ab42 oligomers and fibrils were incubated
a l o n eo rw i t hi m m u n es e r af r o mW S N - A b1-10 (experi-
ment) or WSN-WT (control) immunized mice for 1 h
at room temperature with occasional mixing to ensure
maximal interaction. After incubation, the peptide/
immune sera mixtures were diluted into culture media
so that the final concentration of peptide and antibodies
was 2 μMa n d0 . 2μM, respectively. This media was
then added (100 μl) to SH-SY5Y cells. The treatment
time was 18 h. Untreated controls were run in parallel.
Following incubation, neurotoxicity was assayed using
the MTT assay according to the manufacturer’s instruc-
tions (Promega Corp., WI). The absorbance at 570 nm
was measured by Synergy HT Microplate reader (Biotek,
VT). Cell viability was calculated by dividing the absor-
bance of wells containing samples by the absorbance of
wells containing medium alone.
Statistical Analysis
Statistical parameters (mean, standard deviation (SD),
significant difference, etc.) were calculated using Prism
3.03 software (GraphPad Software, Inc., CA). Statistically
significant differences were examined using a t-test or
analysis of variance (ANOVA) and Tukey’sm u l t i p l e
comparisons post-test (a P value of less than 0.05 was
considered significant).
Results
Generation and characterization of chimeric viruses
expressing Ab1-10 or Ab1-7 peptides
Previous approaches to develop AD active vaccines
based on full-length b-amyloid have resulted in patholo-
gical autoimmunity [8,9,14-16]. To improve the safety
profile of AD vaccines, we have constructed chimeric
influenza virus A/WSN/33 (H1N1) expressing B cell epi-
topes of Ab42,A b1-10 (WSN-Ab1-10)a n dA b1-7 (WSN-
Ab1-7) using plasmid-based reverse genetic techniques
described above. Influenza virus contains 200-300 mole-
cules of HA per virion, with each of them possessing 5
antigenic sites that induce majority of neutralizing anti-
body responses [33]. On the other hand, the immunodo-
minant B cell epitope of Ab42 has been mapped to the
N terminus of this peptide [30,34-40] and, importantly,
these peptides do not possess T helper epitope/s [35,41].
Accordingly, Ab1-10 (Figure 1A) and Ab1-7 (data not
shown) epitopes of Ab42, were inserted into one of five
HA antigenic sites between amino acids 171 and 172.
The other four antigenic sites of HA remained unaltered
so they could induce virus-neutralizing antibodies. Gen-
erated chimeric viruses were purified and the expression
of inserted antigens was tested. As shown in Figure 1B,
coomassie staining of SDS-PAGE resolved purified
viruses revealed that the purity of both chimeric (WSN-
Ab1-10) and wild-type (WSN-WT) viruses reached to >
90%. Immunoblot analysis conducted with anti-Ab
monoclonal antibody (20.1) demonstrated that chimeric,
but not WT, virus expressed an Ab peptide incorpo-
rated into the viral protein (HA) (Figure 1C), while both
viruses expressed HA, NP and M1 proteins detected
with anti-WSN antibodies (Figure 1D). Of note, to make
it simple, only data with WSN-Ab1-10,b u tn o tW S N -
Ab1-7 were presented in Figure 1.
Next, we compared the ability of WT virus and Ab
peptide expressing chimeric viruses to infect the host
cells in vitro by immunofluorescence assay. MDCK cells
mock-infected or infected with WSN-WT, WSN-Ab1-10
or WSN-Ab1-7 were stained with either anti-Ab (20.1)
or anti-HA (2G9) monoclonal antibodies (Figure 2.).
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only with anti-HA antibody. WSN-Ab1-10 or WSN-Ab1-
7 infected cells stained positive for Ab and anti-HA (Fig-
ure 2). These data supported biochemical results pre-
sented in Figure 1 and also suggested that the insertion
of Ab peptide into the HA molecule did not perturb the
infectivity of the chimeric flu virus. A hemagglutination
inhibition (HI) assay (Figure 3) was next conducted to
analyze the impact of the Ab insertion in recognition of
the HA by neutralizing antibodies. Interestingly, anti-Ab
monoclonal antibody (20.1) inhibited hemagglutination
of chicken red blood cells (RBC) by WSN-Ab1-10 or
WSN-Ab1-7 viruses, but not by WSN-WT (Figure 3).
The anti-HA monoclonal antibody (2G9) inhibited
hemagglutination of RBC by chimeric and wildtype
viruses, whereas a negative control antibody specific for
Figure 2 Expression of b-amyloid B cell epitopes by chimeric influenza virus WSN (WSN-Ab1-10 and WSN-Ab1-7). MDCK cells infected
with WSN-Ab1-10 and WSN-Ab1-7 were positive for immunostaining with anti-Ab and anti-HA antibodies, whereas cells infected with WSN-WT
were positive only with anti-HA antibody.
Figure 3 Anti-HA antibodies inhibited agglutination of RBC by both wild-type and chimeric influenza viruses, while anti-Ab antibodies
only inhibited agglutination of RBC by the chimeric virus.
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demonstrate that (i) the Ab epitope is displayed on the
virus surface allowing for the recognition by anti-Ab
antibodies and (ii) the insertion of Ab peptide did not
drastically change the conformation of the HA molecule
and did not disturb its functional ability.
WSN-Ab1-10 is more immunogenic than WSN-Ab1-7
To evaluate the ability of chimeric influenza viruses
expressing Ab1-10 and Ab1-7 peptides to induce anti-Ab
antibody responses, C57Bl/6 mice were immunized with
20 μg/mouse purified inactivated chimeric viruses (for-
mulated in a strong Th1 type adjuvant, QuilA, three
times with two weeks interval (Table 1, Study 1).
Control groups of mice were immunized with 20 μg/
mouse of inactivated purified WSN-WT. An Ab-specific
ELISA revealed that both chimeric influenza viruses
expressing Ab1-10 or Ab1-7 induced anti-Ab antibody
responses after three immunizations; however, antibody
responses were significantly stronger for WSN-Ab1-10
immunized mice as compared to WSN-Ab1-7 immu-
nized mice (Figure 4). No anti-Ab response was seen in
the control group of mice immunized with WSN-WT
(Figure 4). Based on the higher ELISA titer, the chimeric
influenza virus WSN-Ab1-10 was chosen for further
experiments.
Humoral immune responses generated by WSN-WT and
WSN-Ab1-10 vaccines are dose-dependent
Next we investigated the effects of an increased anti-
g e nd o s eo ng e n e r a t i o no fa n t i - A b and anti-influenza
antibodies (Table 1, Study 2). C57Bl/6 mice were
immunized with three different doses (5 μg, 25 μga n d
50 μg per mouse) of WSN-Ab1-10 or WSN-WT.
Humoral immune responses were evaluated in all
groups after the third immunization (Figure 5). Immu-
nizations with 5 μg/mouse or 25 μg/mouse doses of
WSN-Ab1-10 induced relatively low levels of anti-Ab
antibodies (7.47 ± 5.29 μg/ml and 9.47 ± 3.52 μg/ml,
respectively). However, 50 μg / m o u s ed o s eo fW S N -
Ab1-10 (40.01 ± 35.66 μg/ml) induced strong anti-Ab
antibody response that was significantly higher (P ≤
0.05) than that in mice vaccinated with 5 μg/mouse or
25 μg/mouse doses (Figure 5A). Both 25 μg/mouse and
50 μg/mouse doses of WSN-Ab1-10 induced signifi-
cantly higher (P ≤ 0.05) titers of anti-WSN antibody
(~75,000 and ~80,000, respectively) than that in mice
immunized with 5 μg/mouse dose of WSN-Ab1-10
(~45,000) (Figure 5B). Of note, although the anti-WSN
antibody response was slightly higher in mice immu-
nized with 50 μgW S N - A b1-10 compared with that in
mice immunized with 25 μgW S N - A b1-10, this differ-
ence was not significant. In case of immunization with
WSN-WT virus the dose-dependent nature of humoral
response was more evident. 50 μg/mouse of WSN-WT
induced significantly higher titers of anti-influenza
antibodies (~125,000) than 25 μg/mouse (~110,000, P
≤ 0.05) and 5 μg/mouse doses (~25,000, P ≤ 0.001),
respectively (Figure 5C). Thus, mice immunized with
50 μg of inactivated chimeric virus generated the
strongest anti-amyloid and anti-influenza humoral
immune responses and this dose of vaccine have been
used in our further experiments described below.
Kinetics of antibody responses in mice immunized with
WSN-WT and WSN-Ab1-10 viruses
The kinetics of anti-Ab antibody and anti-influenza anti-
body responses in mice vaccinated with WSN-Ab1-10 or
WSN-WT were analyzed to determine the minimal
number of vaccinations required to achieve maximal
humoral responses and to determine if a correlation
existed between the kinetics of Ab antibody and influ-
enza virus HA responses. Two groups of mice were
immunized six times biweekly with inactivated WSN-
Ab1-10 or WSN-WT formulated in Quil A adjuvant
(Table 1, Study 3). The concentration of anti-Ab antibo-
dies was measured in sera of mice after each immuniza-
tion starting from the second immunization (Figure 6A).
The highest Ab antibody titer was detected after the 3
rd
immunization with WSN-Ab1-10 (56.47 ± 30.18 μg/ml).
Further immunizations did not change the level of anti-
Ab antibodies as the titers reached a plateau (after 6
th
immunization titers were still the same = 46.43 ± 42.66
μg/ml). As expected, WSN-WT immunized mice did
not show any detectable anti-Ab antibody responses
(data not shown).
Importantly, immunization with WSN-Ab1-10 elicited
also high titers of anti-WSN antibodies after the second
Table 1 Design of immunization studies in wild-type mice
Study Group Immunogen Dosage
(μg/
mouse)
Total number of
Immunizations
Study
1
1 WSN-WT 20 3
2 WSN-Ab1-7 20 3
3 WSN-Ab1-10 20 3
Study
2
1 WSN-WT 5 3
2 WSN-WT 25 3
3 WSN-WT 50 3
4 WSN-Ab1-10 53
5 WSN-Ab1-10 25 3
6 WSN-Ab1-10 50 3
Study
3
1 WSN-WT 50 6
2 WSN-Ab1-10 50 6
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each subsequent immunization reaching up to ~125,000
after six immunizations (Figure 6B). In contrast, WSN-
WT immunization elicited the highest level of anti-influ-
enza antibody much quicker (after 4
th immunization
titer of antibodies was ~125,000), which then decreased
after 5
th and 6
th immunizations (Figure 6B). Thus,
although after early immunizations the titers of anti-
influenza antibodies were significantly higher in mice
immunized with WSN-WT than with WSN-Ab1-10,t h e
pattern was changed after further immunizations. Inter-
estingly, after the 6th immunizations titers of anti-
Figure 4 Mice immunized with killed WSN-Ab1-10 virus generated significantly higher anti-Ab42 specific antibodies compared with that
in mice immunized with WSN-Ab1-7. Anti-Ab antibody responses were measured in sera of individual mice immunized 3 times with indicated
viruses at dilution 1:200. Lines represent the average (n = 5, *P < 0.05; **P < 0.01).
Figure 5 Anti-Ab and anti-WSN immune responses in mice immunized with different doses of WSN-Ab1-10 and WSN-WT: Anti-Ab (A)
and anti-WSN (B, C) antibodies were analyzed in sera of individual mice immunized 3 times with indicated doses of killed WSN-Ab1-10 and WSN-
WT viruses formulated in Quil A. Lines and error bars indicate the average ± s.d. (n = 6 for groups immunized with 5 and 25 μg and n = 16 for
groups immunized with 50 μg killed viruses (*P < 0.05; ***P < 0.001).
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cantly higher than that elicited by WSN-WT.
Anti-Ab and anti-influenza antibodies are therapeutically
potent
To show the therapeutic potential of dual chimeric
vaccine we first analyzed binding of antisera to Ab pla-
ques in brain tissue from an AD case. As we expected
from our previous studies [20,22,24], sera generated
after immunizations of mice with WSN-Ab1-10 bound
to b-amyloid plaques very well (Figure 7A). This bind-
ing was specific to Ab since it was blocked by pre-
absorption of antisera with Ab42 peptide (Figure 7B).
As one could expect from data presented above, sera
obtained from mice immunized with WSN-WT did
not bind to Ab deposits in AD brain tissue at all (Fig-
ure 7C).
The important feature of functional anti-Ab antibody
is the binding to all species of Ab42 peptide and inhibi-
tion of cytotoxic effect of Ab42 oligomers and fibrils on
human neuroblastoma SH-SY5Y cells. We demon-
strated that immune sera from mice immunized with
WSN-Ab1-10 bound very well to monomeric, oligo-
meric and fibrillar forms of Ab42 peptide in a dot blot
assay (Figure 8A). Thus, we confirmed that WSN-Ab1-
10 vaccine induced anti-Ab antibodies capable of bind-
ing not only to Ab42 oligomers and fibrils in vitro,b u t
also to plaques of AD case. These data suggested that
anti-Ab antibody generated by WSN-Ab1-10 vaccine is
therapeutically potent and might exhibit a protective
effect on Ab-induced neurotoxicity. To test that, we
performed in vitro assessment using human neuroblas-
toma SH-SY5Y cells. The data showed that both Ab42
fibrils and oligomers are cytotoxic, reducing cell
Figure 6 Kinetics of anti-Ab (A) and anti-WSN-WT antibody responses (B) in mice immunized with 50 μg/mouse of WSN-Ab1-10 and
WSN-WT viruses. Concentration of anti-Ab antibodies and half-maximal titers (HMAT) of anti-WSN-WT antibodies were analyzed in individual
mice. HMAT was determined in the sera of individual mice by dividing the highest OD450 value in the dilution range of each sample by two.
Initial dilution of sera in these experiments was 1:500 and they were serially diluted up to 1:500000. Error bars indicate the average ± s.d. n = 16
and n = 8 in groups immunized with WSN-Ab1-10 and WSN-WT viruses respectively (**P < 0.01, ***P < 0.001).
Figure 7 Therapeutic potency of anti-Ab antibody generated in mice immunized with WSN-Ab1-10: (A) Immune sera generated after
immunization with killed WSN-Ab1-10 (at dilution 1:600) bound to the brain sections of cortical tissues from an AD case and (B) this binding was
blocked by pre-absorption of sera with Ab42 peptide. (C) Immune sera generated after immunization with killed WSN-WT (at dilution 1:600) did
not bind to the brain sections of cortical tissues from an AD case. Original magnification was ×4 and scale bar was 200 μm.
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8B). Pre-incubation of Ab42 fibrils with immune sera
from WSN-Ab1-10 vaccinated mice resulted in the res-
cue of cell viability to maximum level (~97.5%). Simi-
larly, pre-incubation of Ab42 oligomers with anti-Ab1-
10 antibody increased cell viability to approximately
90.9%. In contrast, pre-incubation of both Ab42 species
with immune sera from WSN-WT immunized mice
(control) did not rescue cells from oligomer or fiber-
mediated cell death. These data suggest that anti-Ab1-
10 antibody generated by WSN-Ab1-10 chimeric vaccine
inhibits Ab42 fiber-mediated neurotoxicity and allevi-
ates oligomer-mediated toxicity in vitro.
Next in order to understand the dual potency of
WSN-Ab1-10 it was important to analyze the anti-viral
efficacy of antibodies generated by the chimeric vaccine.
The level of neutralizing anti-viral antibodies in immu-
nized mice was measured using the HI assay described
above. HI antibody titers were determined in groups
immunized with different doses (5 μg, 25 μg, or 50 μg)
of chimeric and wildtype viruses against both types of
viruses: WSN-Ab1-10 and WSN-WT (Table 1, Study 2).
After 3 immunizations all mice had measurable titers (>
1:40) of HI antibodies against both viruses. The titers of
HI antibody in pre-bleed sera were < 1:10 (data not
shown). Immunization with 50 μg/mouse WSN-Ab1-10
Figure 8 Antibodies generated in mice immunized with dual vaccine, WSN-Ab1-10 bind to Ab42 and inhibit its neurotoxicity: (A) Sera
isolated from WSN-Ab1-10, but not WSN-WT vaccinated mice at dilution 1:200 bound to all species of Ab42 peptide, including oligomers
recognized by A11 oligomer-specific antibodies. Control monoclonal 6E10 antibody bound to all forms of Ab42 peptide. (B) Anti-Ab1-10 inhibits
Ab42 fibrils- and oligomer-mediated toxicity. Human neuroblastoma SH-SY5Y cells were incubated with Ab42 oligomers and Ab42 fibrils, in the
presence or absence of anti-Ab1-10 antibody or irrelevant mouse IgG. Control cells were treated with the vehicle, and cell viability was assayed in
all cultures using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Data were collected in four replicate and was expressed
as a percentage of control ± s.d.
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against both wild-type and chimeric viruses than the
immunizations by 5 μg/mouse and 25 μg/mouse doses
of WSN-Ab1-10 (P ≤ 0.05 and P ≤ 0.01, respectively, Fig-
ure 9A, B). No significant differences in titers of HI
antibodies against both chimeric and wild type WSN
viruses were observed in mice immunized with three
different doses of WSN-WT (Figure 9A and 9B). The
kinetics of anti-HA neutralizing antibodies were also
analyzed in the sera of mice immunized with 50 μg/
m o u s ed o s a g eo fW S N - A b1-10 and WSN-WT (Table 1,
Study 3). The titers of HI antibodies were measured
after two, three and four immunizations against WSN-
WT (Figure 10A) and WSN-Ab1-10 (Figure 10B) viruses
using HI assay. Both viruses elicited equal titers of func-
tional anti-HA antibodies inhibiting hemagglutination
by wild-type virus. However, titers of functional antibo-
dies inhibiting hemagglutination by WSN-Ab1-10 virus
was significantly higher in mice immunized with WSN-
Ab1-10 than in mice immunized with WSN-WT (P ≤
0.01 and P ≤ 0.05 after 3
rd and 4
th immunizations,
respectively, Figure 10B). Thus, chimeric WSN-Ab1-10
vaccine was at least as good as WSN-WT in generation
of virus neutralizing antibodies, however it had an addi-
tional benefit as it also induced therapeutically potent
anti-AD antibodies.
Discussion
Different approaches that aimed to prevent Ab over-
production or accelerate its degradation are currently
being developed for treatment of AD. However all avail-
able treatments have only relatively small symptomatic
benefits and could not delay or halt the progression of
the disease. As a result, there is no cure from AD today.
A potentially powerful strategy is immunotherapy with
anti-Ab antibody that can facilitate the reduction of
pathological forms of Ab in the brain [42-52] via several
pathways, including catalytic dissolution of amyloid
deposits by antibodies; Fc mediated macrophage phago-
cytosis of amyloid; non-Fc mediate macrophage amyloid
clearance; a peripheral sink, whereby Ab is drawn out of
the brain into the peripheral circulation [53,54].
The results of the first AD clinical trial using the AN-
1792 vaccine confirmed that anti-Ab antibodies are ben-
eficial for AD patients and may at least slow the pro-
gression of a disease. However this trial raised concerns
about the safety and the efficacy of the active immuniza-
tion strategy with Ab42 self-peptide. Although the
results from the Phase I trial showed good tolerability,
in the phase IIa portion of the AN-1792 immunotherapy
a subset of individuals developed adverse events in the
central nervous system [8-11,14-17]. Further examina-
tions demonstrated that these adverse effects were pre-
sumably due to the infiltration of autoreactive T cells,
rather than anti-Ab antibody. In addition, the relatively
low antibody titers generated even after multiple immu-
nizations and non-responsiveness in ~80% of patients
indicating that the Ab self-antigen vaccine was not a
strong immunogen, suggest that alternative immu-
notherapeutic strategies should be pursued.
Based on data that the immunodominant B cell epi-
tope of Ab42 has been mapped to the N-terminus of
this peptide (aa spanning residues 1-5, 1-7, 1-8, 1-11, 1-
15, 1-16, or 4-10) [34,35,37,39,55] and that this Ab1-11
peptide does not contain a T cell epitope in mice [35]
or in humans [56], we proposed to use a prototype epi-
tope vaccine that contains the small immunodominant
self-B cell epitope of Ab in tandem with promiscuous
Figure 9 Antibodies generated in mice immunized with dual vaccine, WSN-Ab1-10 neutralize both WSN-WT (A)a n dW S N - A b1-10 (B)
viruses. Titers of HI antibody against WSN-WT (A) or WSN-Ab1-10 (B) viruses were measured in individual mice (n = 6/per group) after 3
immunizations. The statistical difference between each group was determined (*P < 0.05; **P < 0.01).
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risk of an adverse T cell-mediated immune response to
Ab-immunotherapy [20]. The efficacy and immunogeni-
city of our peptide and DNA-based epitope vaccines
have been previously tested in the pre-clinical trials
[23-25]. Other groups of scientists and different phar-
maceutical companies are working on development of
epitope-based AD vaccines composed of self-Ab B cell
epitope attached to the carrier protein rather than small
foreign Th epitope [57]. Another category of epitope
vaccines are those based on viral-like particles (VLP)
[58-61]. Incorporation of the Ab B cell epitope into a
viral capsid protein or scaffold proteins allows the
expression of this epitope on the surface of VLP in a
repetitive and ordered array. Such organization of the
epitope may induce T cell-independent B cell activation
and production of anti-Ab antibodies of IgM isotype.
On the other hand, T cell epitopes from the viral pro-
teins may help B cells to induce T cell-dependent
humoral responses and produce antibodies of other iso-
types. In fact, high titers of persisting long-term anti-Ab
antibodies were induced by recombinant protein based
on pyruvate dehydrogenase complex of B. stearothermo-
philus fused with Ab1-11 B cell epitope. This protein self
assembles in vitro into a high molecular mass scaffold
with icosahedral symmetry exposing Ab B cell epitope
on a surface [62]. Therapeutically potent anti-Ab antibo-
dies (up to 1:10000 titer) were generated in APP/Tg
mice using VLP based on papillomavirus [58,61], retro-
virus [59], Qb bacteriophage [58,60]. Qb-based vaccine
comprising the Ab1-6 epitope (CAD106) covalently
linked to VLPs [63] is currently in Phase II clinical trials
conducted by Novartis. Report from Phase I trial on
safety, tolerability and Ab-specific antibody responses in
a group of patients with mild to moderate AD following
three subcutaneous injections of 50 μg( c o h o r tI )a n d
150 μg (cohort II) CAD106 was encouraging and
showed that adverse events were predominantly mild.
Although CAD106 induced low titers of specific anti-
body with a 2-fold increase in cohorts II vs I, 16/24 and
18/22 of subjects in cohort I and cohort II, respectively,
responded to the vaccine [64,65].
Our chimeric vaccine strategy described in this paper
is different from VLP-based vaccines. First of all it is
based on whole chimeric virus instead of non-replicative
particles and therefore it could be used as either killed
or live attenuated virus based vaccine. The use of chi-
meric influenza viruses whose backbone is widely used
as a human influenza vaccine has the advantages of hav-
ing quite well known antigenic properties in humans, of
its immunogenicity being helped in humans by memory
T cell responses against the backbone virus. More
importantly, our strategy aimed to generate dual vaccine
and test the feasibility of this approach.
Accordingly, we decided to take advantage from our
previously developed plasmid-based reverse genetic
technique [26] and generate a dual vaccine expressing
the short B-cell epitope of amyloid within the HA of
influenza virus. The HA and NA glycoproteins of influ-
enza A viruses contain the major antigenic determinants
of the virus responsible for the induction of neutralizing
(protective) immune response. The appropriate muta-
tions or insertions that may attenuate virus without
compromising the immunogenicity of the vaccine
allowed generating chimeric viruses (vectors) that can
express heterologous polypeptides [66]. Because influ-
enza viruses are potent inducers of antigen-specific B
and T cell immune responses [66] they can also be
Figure 10 Virus neutralization titers of sera generated after 2, 3 and 4
th immunizations with dual vaccine and WSN-WT are the same.
HI titers against WSN-WT (A) and WSN-Ab1-10 (B) were evaluated in sera of individual mice immunized after 2, 3, and 4 immunizations with
WSN-WT (close sq) or WSN-Ab1-10 (open sq). Error bars indicate the average ± s.d. for mice immunized with WSN-Ab1-10 (n = 16) or WSN-WT (n
=8 )(*P <0.01; **P < 0.01).
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cell epitope. In fact, previously it was shown that appro-
priate chimeric influenza viruses delivered heterologous
small antigen (usually about 10-12 aa) into the host [67]
and induced potent antibody [68] or cellular [69]
immune responses specific to grafted peptide.
Here we generated and studied dual vaccines based on
chimeric viruses, expressing Ab1-10 or Ab1-7 epitopes of
Ab42. These B-cell epitopes of amyloid-b were inserted
between amino acids 171 and 172 of HA, while the
other four antigenic sites of HA remained intact (Figure
1A). The WB analysis demonstrated that chimeric, but
not WNT-WT virus expressed HA of correct size con-
taining Ab1-10 (Figure 1C) or Ab1-7 (data not shown)
peptides. Importantly, the insertion of Ab into HA did
not change the capability of virus to infect host MDCK
cells (Figure 2) or the conformation of the HA molecule
(Figure 2 and 3).
Next we decided to analyze the immunogenic potency
of the chimeric virus and compare it with that of wild-
type influenza virus. Purified WSN-Ab1-10,W S N - A b1-7,
or WSN-WT viruses (Figure 1B and data not shown)
has been used for preparation of inactivated vaccines
that have been formulated into Th1 type adjuvant prior
to immunization of experimental and control mice. We
demonstrated that WSN-Ab1-10 was more immunogenic
than WSN-Ab1-7 (Figure 4) and it induced the highest
titers of anti-amyloid and anti-viral antibodies at 50 μg/
m o u s ed o s e( F i g u r e5 ) .W S N - A b1-10 induced as good
anti-viral humoral immune responses as WSN-WT after
3-4 immunizations (Figure 5, 6). These results support
our hypothesis that chimeric influenza virus could be an
excellent delivery platform for Ab epitope, and at the
same time provide T helper cell help to Ab specific B
cells. Of note, using peptide, recombinant protein and
DNA based epitope vaccines we showed that Ab1-11
region did not possess epitopes for H2-b and H-2d mice
[20,23,25]. More importantly, it was shown that Th epi-
tope of Ab42 mapped to C-terminal region of this pep-
tide [56]. Based on these data currently several
companies are conducting Phase I/IIa studies with car-
riers fused with N-terminal regions of amyloid [70,71].
The data represented above implied that a dual vac-
cine strategy is feasible since vaccinations of mice
induced strong anti-viral and anti-amyloid humoral
immune responses. At the same time these results did
not demonstrate the therapeutic potency of anti-influ-
enza and anti-Ab antibodies. To test that, we performed
in vitro assessment using HI [29] and neurotoxicity
[24,32] assays routinely used in our laboratories. These
analyses showed that chimeric virus maintained the abil-
ity to induce the production of (i) virus neutralizing
antibodies that inhibited the hemagglutination of red
cells by the both chimeric and wild-type viruses (Figure
9, 10); and (ii) anti-Ab antibodies that are binding to
various Ab42 forms (Figure 8A) and inhibiting Ab42
fibrils- and oligomer-mediated toxicity of human neuro-
blastoma SH-SY5Y cells (Figure 8B). Data presented
above suggest that anti-viral antibody could block viral
infection while anti-Ab antibody could be an effective
modulator of Ab42 aggregate formation regardless of the
nature of the aggregated species. Indeed, anti-Ab anti-
body bind not only Ab42 fibrils and oligomers in vitro,
but also Ab plaques present in brain sections of cortical
AD tissue (Figure 7).
To our knowledge this is the first attempt for genera-
tion dual vaccine based on conventional seasonal Flu
vaccine and therefore designed to protect the elderly
from both AD and seasonal Flu infection. Annual
administration of seasonal Flu vaccine is currently pro-
posed, therefore it is important to study the persistence
of anti-Ab antibodies and optimized schedule for vacci-
nation with dual vaccine. However, in mice that are
leaving in average 2.2-3.2 years it is not accurate testing
annual vaccination strategy used for vaccination of
elderly people. Thus, we are currently planning to study
the doses, type of vaccine (killed or live attenuated), as
well as schedule for vaccination in non-human primates,
including aged animals with immunosenescence. The
major complication connected with vaccination of
elderly people is the poor response to the vaccines due
to the immunosenescence. One possible strategy to
counteract the immunosenescence is to recruit pre-
viously generated memory T cells produced during prior
vaccinations and/or exposure to human pathogens. The
majority of people already possess memory T cells spe-
cific for influenza due to yearly vaccinations and/or
infection by virus. Thus, immunization of elderly people
with our dual vaccine may in theory recruit memory T
helper cells specific to influenza epitopes and induce
rapid and potent anti-Ab antibody production, while
continuing to boost anti-viral cellular and humoral
responses. This hypothesis is the subject of studies in
progress in our laboratories.
Another important aspect of a dual vaccine is related
to the safety issues. Since the majority of people
including children and elderly are vaccinated with
influenza vaccine yearly and the safety of this vaccine
is observed for a long period of time, the chance that
the dual vaccine is safe is very high. Finally, we think
that the availability of a safe dual vaccine will allow
the treatment of pre-symptomatic people rather than
AD patients. Based on both preclinical studies and the
results from the AN1792 clinical trials [70,71] we may
assume that early intervention in the disease process,
pre-symptomatic if possible, is likely to be significantly
more beneficial than attempting to intervene in the
disease process after clinical diagnosis of the disease.
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reduce the probability of adverse events in response to
active immunization [14]. We believe that the recent
breakthroughs in the development of biomarkers for
AD provide a hope that patients can be accurately
identified while they are still in the preclinical stages
of AD [72-77], which should facilitate the usage of
dual vaccines before extensive neuronal damage and
cerebral amyloid angiopathy has occurred in the brain
in the general population. At the same time it should
be mentioned that many groups including us have not
observed infiltration of autoreactive T cells (presumed
Th1 response that likely occurred in AN1792 vacci-
nated patients) in the brains after immunizations of
APP/Tg or wild-type mice with the original Schenk et
al. protocol [2] or with other Ab vaccines (unless per-
tussis toxin widely used to induce brain T cell penetra-
tion in experimental autoimmune encephalomyelitis
have been co-administered [78]). Thus, obviously only
clinical trials may help us to conclude that any epitope
vaccine including our chimeric flu vaccine is safe and
do not induce harmful proinflammatory T cell
responses in vaccinated AD patients.
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